Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
Recent Articles
RELATED ARTICLES
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
